Status and phase
Conditions
Treatments
About
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
Full description
Tenalisib is a highly specific and orally available dual PI3K δ/γ inhibitor. Pre-clinical experiments demonstrated that Tenalisib is highly effective in killing primary CLL cells in vitro. A Phase II study is planned to evaluate the efficacy and safety of Tenalisib in patients with relapsed/refractory CLL.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Richter's (large cell) transformation, or PLL transformation.
Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter).
Prior exposure to drug that inhibits PI3K
Patient with ASCT/Allo-SCT receiving treatment for active GVHD.
Ongoing severe systemic bacterial, fungal or viral infection.
Central nervous system (CNS) involvement of leukemia or lymphoma.
Ongoing immunosuppressive therapy including systemic corticosteroids.
Known history of severe liver injury as judge by investigator.
Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation
Women who are pregnant or lactating.
Known seropositive requiring anti-viral therapy for i. human immunodeficiency virus (HIV) infection. ii. hepatitis B virus (HBV) infection iii. hepatitis c virus (HCV) infection iv. active CMV infection
Primary purpose
Allocation
Interventional model
Masking
21 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal